Status:
UNKNOWN
Punch Minigraft Versus Transverse Needling or Combination of Both in Treatment of Non-Segmental Vitiligo
Lead Sponsor:
Alexandria University
Conditions:
Vitiligo
Eligibility:
All Genders
16+ years
Phase:
NA
Brief Summary
This study is to evaluate the effectiveness and tolerability of autologous punch minigraft, transverse needling technique or combination of both followed by narrow band ultraviolet B phototherapy (311...
Detailed Description
Vitiligo is a common pigmentary cutaneous disorder occurring with an incidence of 1-2% worldwide, without predilection for sex or race. The disease is characterized by gradual loss of the normal colo...
Eligibility Criteria
Inclusion
- Adult patients (\>16 years old) of either gender having stable non segmental vitiligo, that is resistant to other lines of repigmentation therapy.
- Lack of progression of old lesions with the past 6 months.
- No development of new lesions
- Absence of history of koebner phenomenon.
- Absence of confetti lesions or hypopigmented lesions within the past 6 months.
- Presence of repigmentation of depigmented areas by medications or spontaneously in the past 6 months.
- While resistance to therapy will be judged after receiving standard protocol of NB-UVB together with oral mini pulse dexamethasone at a dose of 2.5 mg on two consecutive weekly days for 3 months.
- Patients having lesions showing absence or poor repigmentation after this regiment will be considered resistant to medical repigmentation and indicated to surgery.
Exclusion
- Cases of active, progressive disease lacking criteria of stability previously mentioned.
- Patients with segmental or universal vitiligo covering more than 70% body surface area.
- Patients with known associated autoimmune diseases, bleeding tendency, current or history of skin neoplasia, photosensitive disorders or any contraindications to corticosteroids therapy.
- Patients with tendency towards hypertrophic scars or keloid formation.
- Pregnant female and lactating mothers.
- Patients with emotional and psychological instability.
Key Trial Info
Start Date :
February 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03872804
Start Date
February 1 2019
End Date
March 1 2021
Last Update
January 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Omneya abd el aziz el zagh
Alexandria, Egypt, 21500